Pressmeddelanden från Orion

Bevaka pressreleaser

Kurs från TradingView

Start Nyheter Pressreleaser Riktkurser Insynshandel Blankning Analyser Bloggar Videos Podcasts

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)05 mar 14:00

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)27 feb 10:05

Orion Group Financial Statement documents 2025 and Remuneration Report published 12 feb 12:12

The Board of Directors of Orion Corporation decided on a new plan period for the Long-term Incentive program for the company’s key persons 12 feb 11:05

Notice to the Annual General Meeting of Orion Corporation 12 feb 11:00

Orion Group Financial Statement Release January–December 2025 03 feb 08:00

62,752 Orion Corporation A shares converted into B shares 30 jan 08:30

Orion publishes Financial Statement Release for 2025 and holds a webcast on 12 February 2026 20 jan 07:30

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)16 jan 08:30

182,827 Orion Corporation A shares converted into B shares 15 jan 15:30

Recommendation by the Orion Nomination Committee on the proposals to be presented to the 2026 Annual General Meeting 14 jan 15:00

Orion updates time estimate for the potential related to the annual Nubeqa® net sales recorded by Orion 14 jan 07:30

Inside information: Orion provides outlook for 2026 and estimates that the annual Nubeqa® net sales recorded by Orion has potential to exceed EUR 1 billion in the future 13 jan 15:30

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)12 jan 14:00

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)09 jan 15:00

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)08 jan 14:00

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)08 jan 11:00

Orion Pharma announces the initiation of TEADES Phase 2 trial of ODM-212 in Malignant Pleural Mesothelioma (MPM) and Epithelioid Hemangioendothelioma (EHE)07 jan 15:30

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)07 jan 07:30

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)31 dec 2025 12:00

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)30 dec 2025 13:00

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)23 dec 2025 15:00

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)15 dec 2025 13:30

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)09 dec 2025 16:30

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)08 dec 2025 14:30

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)05 dec 2025 16:00

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)03 dec 2025 08:00

Inside information: Orion to receive EUR 180 million milestone and updates full-year outlook for 2025 27 nov 2025 08:00

71,498 Orion Corporation A shares converted into B shares 14 nov 2025 12:30

Orion receives award for international growth from the President of the Republic of Finland 28 okt 2025 11:00

Orion Group Interim Report January–September 2025 24 okt 2025 08:00

49,164 Orion Corporation A shares converted into B shares 23 okt 2025 14:30

Orion and Abzena announce exclusive commercial license for Abzena’s antibody 14 okt 2025 10:15

Orion publishes Interim Report for January–September 2025 and holds a webcast on 28 October 2025 30 sep 2025 12:00

Orion’s phase 2 study of ODM-105 in insomnia did not meet primary goal 30 sep 2025 08:00

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)26 sep 2025 15:30

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)19 sep 2025 08:00

80,802 Orion Corporation A shares converted into B shares 20 aug 2025 08:00

337,000 Orion Corporation A shares converted into B shares 08 aug 2025 08:30

Orion Corporation: Managers’ transactions – Juhani Kankaanpää 04 aug 2025 15:10

Orion Corporation: Managers’ transactions – Satu Ahomäki 21 jul 2025 09:30

Darolutamide receives EU approval in third indication for patients with advanced prostate cancer 18 jul 2025 11:00

Orion Group Half-Year Financial Report January–June 2025 18 jul 2025 08:30

Orion Corporation’s financial reporting and Annual General Meeting in 2026 09 jul 2025 12:00

Inside information: Orion upgrades full-year outlook for 2025 04 jul 2025 08:00

Orion publishes Half-Year Financial Report for January–June 2025 and holds a webcast on 18 July 2025 23 jun 2025 08:30

141,959 Orion Corporation A shares converted into B shares 20 jun 2025 12:30

CHMP recommends third indication for darolutamide for patients with advanced prostate cancer 17 jun 2025 08:00

Orion and Glykos announce the extension of their research collaboration and licensing agreement for the development of next-generation ADCs 03 jun 2025 22:30

U.S. FDA approves third indication of darolutamide for patients with advanced prostate cancer 23 maj 2025 11:40

Orion announces agreement with Shilpa Medicare for Recombinant Human Albumin for European market 22 maj 2025 09:15

Orion to host Capital Markets Day today, 22 May 2025, in Helsinki 21 maj 2025 06:30

Orion’s collaborator, MSD, expands clinical development program for opevesostat to women’s cancers 08 maj 2025 15:30

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)07 maj 2025 16:00

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)06 maj 2025 17:00

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)05 maj 2025 16:00

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)02 maj 2025 14:15

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)02 maj 2025 10:45

Orion Corporation: Managers’ transactions – Eija Ronkainen 02 maj 2025 10:45

Orion Corporation: Managers’ transactions – Ari Lehtoranta 02 maj 2025 10:45

Orion Corporation: Managers’ transactions – Kari Jussi Aho 02 maj 2025 10:45

Orion Corporation: Managers’ transactions – Veli-Matti Mattila 02 maj 2025 10:45

Orion Corporation: Managers’ transactions – Henrik Stenqvist 02 maj 2025 10:45

Orion Corporation: Managers’ transactions – Maziar Mike Doustdar 02 maj 2025 10:45

Orion Corporation: Managers’ transactions – Karen Lykke Sørensen 02 maj 2025 10:45

Orion Corporation: Managers’ transactions – Hilpi Rautelin 02 maj 2025 08:00

301,521 Orion Corporation A shares converted into B shares 25 apr 2025 16:20

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)25 apr 2025 08:00

Orion and Criceto Announce a License Agreement for APORON®, an Innovative Apomorphine Spray to Treat OFF Episodes in Parkinson’s Disease 24 apr 2025 10:00

Composition of the Nomination Committee of Orion Corporation 23 apr 2025 11:00

Orion Group Interim Report January–March 2025 22 apr 2025 08:00

Invitation to Orion’s Capital Markets Day on 22 May 2025 15 apr 2025 09:00

Statutory negotiations at Orion's R&D unit in Turku, Finland have been concluded 10 apr 2025 12:15

The Helsinki Court of Appeal sentenced a member of Orion's Board of Directors to a fine for a securities market information offence 09 apr 2025 12:30

Orion publishes Interim Report for January–March 2025 and holds a webcast on 23 April 2025 03 apr 2025 15:25

Orion Corporation: Organising meeting of the Board of Directors 03 apr 2025 15:20

Decisions taken by Orion Corporation’s Annual General Meeting on 3 April 2025 21 mar 2025 14:00

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)21 mar 2025 12:00

Pharmaceutical industry delivers value proposition to Finnish Government: billions to be invested by 2030 20 mar 2025 14:30

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)19 mar 2025 13:30

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)17 mar 2025 16:15

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)14 mar 2025 14:30

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)13 mar 2025 15:45

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)12 mar 2025 15:15

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)11 mar 2025 10:15

Orion Group Financial Statement documents 2024 and Remuneration Report published 11 mar 2025 08:00

Orion Corporation: Managers’ transactions – Olli Huotari 11 mar 2025 08:00

Orion Corporation: Managers’ transactions – Juhani Kankaanpää 11 mar 2025 08:00

Orion Corporation: Managers’ transactions – Outi Vaarala 11 mar 2025 08:00

Orion Corporation: Managers’ transactions – Liisa Hurme 11 mar 2025 08:00

Orion Corporation: Managers’ transactions – Satu Ahomäki 11 mar 2025 08:00

Orion Corporation: Managers’ transactions – René Lindell 11 mar 2025 08:00

Orion Corporation: Managers’ transactions – Niclas Lindstedt 11 mar 2025 08:00

Orion Corporation: Managers’ transactions – Hao Pan 11 mar 2025 08:00

Orion Corporation: Managers’ transactions – Julia Macharey 10 mar 2025 18:00

Orion Corporation: Transfer of 191,911 own B shares on 10 March 2025 10 mar 2025 16:00

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)10 mar 2025 10:45

Orion to open new Biologics R&D Centre in Cambridge, UK in 2025 to support global growth strategy, considers reorganizing some work in Turku 05 mar 2025 16:00

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)05 mar 2025 08:00

Orion and Aiforia extend collaboration to preclinical study evaluations